PACB Pacific Biosciences Of California Inc
Price (delayed)
$1.17
Market cap
$348.49M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.13
Enterprise value
$964.86M
Pacific Biosciences of California, Inc. is empowering life scientists with highly accurate long-read sequencing. The company's innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a
Highlights
The debt is down by 28% year-on-year and by 27% since the previous quarter
The EPS has grown by 23% from the previous quarter and by 7% YoY
The company's equity fell by 28% YoY but it rose by 12% QoQ
The gross margin has grown by 14% from the previous quarter but it has contracted by 8% YoY
Pacific Biosciences Of California's gross profit has decreased by 29% YoY
The quick ratio has contracted by 24% from the previous quarter and by 10% YoY
Key stats
What are the main financial stats of PACB
Market
Valuations
Earnings
Shares outstanding
297.85M
Market cap
$348.49M
Enterprise value
$964.86M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.63
Price to sales (P/S)
2.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.26
Revenue
$154.01M
Gross profit
$37.28M
Operating income
-$475.16M
Net income
-$309.85M
EBIT
-$296.12M
EBITDA
-$242.77M
Free cash flow
-$212.25M
Per share
Balance sheet
Liquidity
EPS
-$1.13
EPS diluted
-$1.59
Free cash flow per share
-$0.77
Book value per share
$1.85
Revenue per share
$0.56
TBVPS
$2.02
Total assets
$1.26B
Total liabilities
$753.85M
Debt
$672.43M
Equity
$506.59M
Working capital
$429.38M
Debt to equity
1.33
Current ratio
7.48
Quick ratio
6.31
Net debt/EBITDA
-2.54
Margins
Efficiency
Dividend
EBITDA margin
-157.6%
Gross margin
24.2%
Net margin
-201.2%
Operating margin
-308.5%
Return on assets
-21%
Return on equity
-59%
Return on invested capital
-21.5%
Return on capital employed
-24.8%
Return on sales
-192.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PACB stock price
How has the Pacific Biosciences Of California stock price performed over time
Intraday
2.63%
1 week
-7.87%
1 month
-10%
1 year
-25%
YTD
-36.07%
QTD
-0.85%
Financial performance
How have Pacific Biosciences Of California's revenue and profit performed over time
Revenue
$154.01M
Gross profit
$37.28M
Operating income
-$475.16M
Net income
-$309.85M
Gross margin
24.2%
Net margin
-201.2%
PACB's operating margin has dropped by 94% year-on-year and by 31% since the previous quarter
The company's operating income fell by 49% YoY and by 17% QoQ
The net margin is down by 32% year-on-year but it is up by 12% since the previous quarter
Pacific Biosciences Of California's gross profit has decreased by 29% YoY
Growth
What is Pacific Biosciences Of California's growth rate over time
Valuation
What is Pacific Biosciences Of California stock price valuation
P/E
N/A
P/B
0.63
P/S
2.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.26
The EPS has grown by 23% from the previous quarter and by 7% YoY
The P/B is 91% below the 5-year quarterly average of 6.8 and 43% below the last 4 quarters average of 1.1
The company's equity fell by 28% YoY but it rose by 12% QoQ
The price to sales (P/S) is 91% lower than the 5-year quarterly average of 22.1 and 35% lower than the last 4 quarters average of 3.2
The revenue has decreased by 23% YoY and by 11% QoQ
Efficiency
How efficient is Pacific Biosciences Of California business performance
The ROE has contracted by 35% YoY but it has grown by 14% from the previous quarter
The ROS has contracted by 27% YoY but it has grown by 13% from the previous quarter
PACB's ROA is down by 27% YoY but it is up by 15% from the previous quarter
The company's return on invested capital rose by 17% QoQ
Dividends
What is PACB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PACB.
Financial health
How did Pacific Biosciences Of California financials performed over time
The company's total assets is 67% higher than its total liabilities
PACB's total liabilities is down by 28% year-on-year and by 24% since the previous quarter
The company's total assets fell by 28% YoY and by 13% QoQ
The debt is 33% greater than the equity
The company's debt to equity fell by 34% QoQ
The debt is down by 28% year-on-year and by 27% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.